Further, a study in colorectal cancer cells, HCT116 (wild-type) and DLD-1 (mutant p53), demonstrated the abrogation of Mortalin–p53 complex formation in MortaparibPlus-treated cells, increasing the levels of p53 mRNA and decreasing the expression of Mortalin, leading to growth arrest/apoptosis. Here, TP53 is linked to colorectal cancer.